BERKELEY HEIGHTS, N.J., April 1, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced that six abstracts highlighting translational and preclinical data for Cyclacel’s cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.
